<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00365287</url>
  </required_header>
  <id_info>
    <org_study_id>2000LS039</org_study_id>
    <secondary_id>MT2000-15</secondary_id>
    <nct_id>NCT00365287</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer</brief_title>
  <official_title>Transplantation of Umbilical Cord Blood From Unrelated Donors in Patients With Hematological Diseases Using a Non-Myeloablative Preparative Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving low doses of chemotherapy and radiation therapy before a donor umbilical&#xD;
      cord blood stem cell transplant helps stop the growth of cancer cells. It also stops the&#xD;
      patient's immune system from rejecting the donor's stem cells when they do not exactly match&#xD;
      the patient's blood. The donated stem cells may replace the patient's immune system and help&#xD;
      destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted&#xD;
      cells from a donor can also make an immune response against the body's normal cells. Giving&#xD;
      antithymocyte globulin before transplant and cyclosporine and mycophenolate mofetil after&#xD;
      transplant may stop this from happening.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects of giving combination&#xD;
      chemotherapy together with total-body irradiation before donor umbilical cord blood&#xD;
      transplant and to see how well they work in treating patients with advanced hematologic&#xD;
      cancer, metastatic breast cancer, or kidney cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the safety of nonmyeloablative preparative regimen comprising&#xD;
           cyclophosphamide, fludarabine, and total-body irradiation with or without anti-thymocyte&#xD;
           globulin, in terms of non-relapse mortality at day 100 post-transplantation, in patients&#xD;
           with advanced hematologic malignancies, metastatic breast cancer, or renal cell cancer&#xD;
           who are undergoing umbilical cord blood transplantation from an unrelated donor.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the hematopoietic recovery and degree of chimerism on days 21, 60, 100, 180,&#xD;
           and 360 post-transplantation.&#xD;
&#xD;
        -  Determine the incidence of grade II-IV and III-IV acute graft-versus-host disease (GVHD)&#xD;
           by day 100 post-transplantation and chronic GVHD at 1 year post-transplantation.&#xD;
&#xD;
        -  Evaluate the risk of relapse at 1 year post-transplantation.&#xD;
&#xD;
        -  Determine overall survival at 1 year post-transplantation.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
        -  Nonmyeloablative preparative regimen: Patients receive cyclophosphamide IV over 2 hours&#xD;
           on day -6 and fludarabine IV over 1 hour on days -6 to -2. Patients also undergo&#xD;
           total-body irradiation on day -1. Some patients* may also receive anti-thymocyte&#xD;
           globulin (ATG) IV twice daily on days -6 to -4.&#xD;
&#xD;
      NOTE: *Patients who have not had prior combination chemotherapy within the past 3 months OR&#xD;
      who only received 1 prior induction course for the treatment of acute lymphoblastic leukemia,&#xD;
      acute myeloid leukemia, myelodysplastic syndromes, or chronic myelogenous leukemia in blast&#xD;
      crisis receive ATG during the preparative regimen.&#xD;
&#xD;
        -  Umbilical cord blood transplantation (UCBT): Patients undergo UCBT from an unrelated&#xD;
           donor on day 0.&#xD;
&#xD;
        -  Graft-versus-host disease prophylaxis: Patients receive cyclosporine IV over 2 hours or&#xD;
           orally 2-3 times daily beginning on day -3 and continuing until day 100 followed by a&#xD;
           taper until day 180. Patients also receive mycophenolate mofetil IV or orally twice&#xD;
           daily beginning on day -3 and continuing until day 30 or until 7 days after engraftment.&#xD;
&#xD;
      After transplantation, patients are followed periodically for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 120 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2000</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as assessed by a non-relapse mortality &lt; 30% within day 100</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hematopoietic recovery and the degree of chimerism at days 21, 60, 100, 180, and 360 after study completion</measure>
  </secondary_outcome>
  <enrollment type="Actual">148</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Kidney Cancer</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>umbilical cord blood transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of 1 of the following:&#xD;
&#xD;
               -  Acute myeloid leukemia (AML), meeting 1 of the following criteria:&#xD;
&#xD;
                    -  In first complete remission (CR1) by morphology AND at high risk, as&#xD;
                       evidenced by 1 of the following:&#xD;
&#xD;
                         -  AML secondary to myelodysplastic syndromes (MDS)&#xD;
&#xD;
                         -  High-risk cytogenetics, such as those associated with MDS or complex&#xD;
                            karyotype&#xD;
&#xD;
                         -  More than 2 courses of therap were required to obtain a CR&#xD;
&#xD;
                    -  In second or greater CR by morphology&#xD;
&#xD;
                    -  In morphologic relapse or persistent disease, defined as &gt; 5% blasts in&#xD;
                       normocellular bone marrow OR any percentage of blasts if blasts have unique&#xD;
                       morphologic markers (e.g., auer rods)&#xD;
&#xD;
                    -  In cytogenetic relapse (without morphologic relapse)&#xD;
&#xD;
               -  Acute lymphoblastic leukemia (ALL), meeting 1 of the following criteria:&#xD;
&#xD;
                    -  In CR1 by morphology AND at high risk, as evidenced by 1 of the following:&#xD;
&#xD;
                         -  High-risk cytogenetics, such as t(9;22), t(1;19), t(4;11), or other MLL&#xD;
                            rearrangements&#xD;
&#xD;
                         -  More than 1 course of therapy was required to obtain a CR&#xD;
&#xD;
                    -  In second or greater CR by morphology&#xD;
&#xD;
                    -  In morphologic relapse or persistent disease as defined for AML&#xD;
&#xD;
                    -  In cytogenetic relapse (without morphologic relapse)&#xD;
&#xD;
               -  Chronic myelogenous leukemia&#xD;
&#xD;
                    -  All types allowed except refractory blast crisis&#xD;
&#xD;
               -  Non-Hodgkin's lymphoma (NHL)&#xD;
&#xD;
                    -  No intermediate- or high-grade NHL or mantle cell NHL that is progressive on&#xD;
                       salvage therapy&#xD;
&#xD;
                    -  Stable disease allowed provided it is non-bulky&#xD;
&#xD;
               -  Hodgkin's lymphoma&#xD;
&#xD;
                    -  No progressive disease on salvage therapy&#xD;
&#xD;
                    -  Stable disease allowed provided it is non-bulky&#xD;
&#xD;
               -  Chronic lymphocytic leukemia&#xD;
&#xD;
               -  Multiple myeloma&#xD;
&#xD;
               -  MDS&#xD;
&#xD;
                    -  Any subtype allowed, including refractory anemia if there is severe&#xD;
                       pancytopenia or complex cytogenetics&#xD;
&#xD;
                    -  Less than 5% blasts&#xD;
&#xD;
                         -  If patient has blasts ≥ 5% then they must undergo induction therapy&#xD;
                            before transplantation&#xD;
&#xD;
               -  Metastatic breast cancer&#xD;
&#xD;
                    -  Disease must have responded to recent chemotherapy OR in plateau after&#xD;
                       response to chemotherapy&#xD;
&#xD;
               -  Renal cell cancer&#xD;
&#xD;
               -  Acquired bone marrow failure syndromes&#xD;
&#xD;
          -  Small percentage of blasts that is equivocal between marrow regeneration vs early&#xD;
             relapse allowed provided there are no associated cytogenetic markers consistent with&#xD;
             relapse (for patients with AML or ALL)&#xD;
&#xD;
          -  Must have a 4/6 HLA-A, -B, and -DRB1 matched unrelated umbilical cord blood donor&#xD;
             available&#xD;
&#xD;
               -  No 5/6 or 6/6 HLA-A , -B, and -DRB1 matched sibling donor available&#xD;
&#xD;
               -  No more than 2 antigen mismatches at the HLA-A, -B, or -DRB1 loci NOTE: A new&#xD;
                  classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ.&#xD;
                  The terminology of &quot;indolent&quot; or &quot;aggressive&quot; lymphoma will replace the former&#xD;
                  terminology of &quot;low&quot;, &quot;intermediate&quot;, or &quot;high&quot; grade lymphoma. However, this&#xD;
                  protocol uses the former terminology.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status 60-100% OR Lansky performance status 50-100% (pediatric&#xD;
             patients)&#xD;
&#xD;
          -  Albumin &gt; 2.5 g/dL&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL (adults) OR creatinine clearance &gt; 40 mL/min (pediatric&#xD;
             patients)&#xD;
&#xD;
               -  Adults with creatinine &gt; 1.2 mg/dL or a history of renal dysfunction must have a&#xD;
                  creatinine clearance &gt; 40 mL/min&#xD;
&#xD;
          -  Transaminases &lt; 5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin &lt; 3 times ULN&#xD;
&#xD;
          -  LVEF ≥ 35%&#xD;
&#xD;
          -  DLCO &gt; 30% of predicted&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No evidence of HIV infection or known HIV-positivity&#xD;
&#xD;
          -  No decompensated congestive heart failure&#xD;
&#xD;
          -  No uncontrolled cardiac arrhythmia&#xD;
&#xD;
          -  No requirement for supplemental oxygen&#xD;
&#xD;
          -  No active, serious infection&#xD;
&#xD;
               -  Recent mold infection (e.g., Aspergillus) allowed provided patient has received ≥&#xD;
                  30 days of appropriate treatment AND infection is controlled and cleared by an&#xD;
                  infectious disease specialist&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior irradiation that precludes the safe administration of 1 additional dose of&#xD;
             200 cGy of total-body irradiation&#xD;
&#xD;
          -  At least 3 months since prior myeloablative bone marrow transplantation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudio G. Brunstein, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>August 16, 2006</study_first_submitted>
  <study_first_submitted_qc>August 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2006</study_first_posted>
  <last_update_submitted>November 27, 2017</last_update_submitted>
  <last_update_submitted_qc>November 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>stage III renal cell cancer</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>refractory anemia</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II mantle cell lymphoma</keyword>
  <keyword>noncontiguous stage II marginal zone lymphoma</keyword>
  <keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>refractory anemia with ringed sideroblasts</keyword>
  <keyword>refractory cytopenia with multilineage dysplasia</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

